Investment Bank Espirito Santo has given a bullish assessment of the prospects for ImmuPharma and its lead drug Lupuzor as it has come up with a 200 pence valuation for the shares.
Only registred members can create thier own customized alerts.
-
-
03/11/11
ImmuPharma chief Dimitriou is very optimistic about Lupuzor future
ImmuPharma chief executive Dimitri Dimitriou said he is very “optimistic about the future” as the company looks to seal a new licensing deal for Lupuzor, its flagship product. He revealed the group had “rekindled discussions” with big pharmaceuticals companies, and he is hopeful a deal can be struck.
-
03/11/11
ImmuPharma says Lupuzor will move into phase III trials with Special Protocol Assessment
Any lingering doubts over Immupharma’s lead drug, Lupuzor, were dispelled this morning when the group announced it would enter phase III clinical trials.
-
21/10/11
ImmuPharma: regaining of Lupuzor rights to bring “a lot more cash into the company”
The drug discovery firm’s chief executive expects more interest from big pharma in its Lupus drug candidate now than when it signed its original deal with Cephalon in 2008
-
21/10/11
ImmuPharma will not have to fund Lupuzor Phase III trial, says Merchant
The broker says that ImmuPharma partner Cephalon has a “moral obligation” in the eyes of the US Food and Drug Administration to complete the clinical trial of the Lupus drug candidate